Disc Medicine (IRON) said Friday it has obtained a $200 million term loan from Hercules Capital (HTGC).
The facility provides funding options to back the expected launch of a confirmatory study of bitopertin in erythropoietic protoporphyria, a phase 2 trial of DISC-0974 in anemia of myelofibrosis and a study in anemia of non-dialysis dependent chronic kidney disease, as well as a phase 2 trial of DISC-3405 in polycythemia vera, the company said.
The loan comprises up to four tranches, three of which can be drawn at the company's option and each maturing in November 2029, the company added.
Shares of Disc Medicine rose nearly 3%, while Hercules Capital shares were marginally higher.
Price: 65.15, Change: +1.82, Percent Change: +2.87
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。